Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review

References

• DavisJMIIIMattesonELAmerican College of Rheumatology, European League Against Rheumatism. My treatment approach to rheumatoid arthritisMayo Clin Proc201287765967322766086
   PubMed Web of Science ®Google Scholar
• AllaireSWolfeFNiuJLavalleyMPContemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the USArthritis Rheum200859447448018383413
   PubMed Web of Science ®Google Scholar
• GabrielSECrowsonCSKremersHMSurvival in rheumatoid arthritis: a population-based analysis of trends over 40 yearsArthritis Rheum2003481545812528103
   PubMed Web of Science ®Google Scholar
• AletahaDNeogiTSilmanAJ2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeArthritis Rheum20106292569258120872595
   PubMed Web of Science ®Google Scholar
• SmolenJSAletahaDBijlsmaJWTreating rheumatoid arthritis to target: recommendations of an international task forceAnn Rheum Dis201069463163720215140
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis201473349250924161836
   PubMed Web of Science ®Google Scholar
• SchellerJChalarisASchmidt-ArrasDRose-JohnSThe pro- and anti-inflammatory properties of the cytokine interleukine-6Biochim Biophys Acta20111813587888821296109
   PubMed Web of Science ®Google Scholar
• AshZEmeryPThe role of tocilizumab in the management of rheumatoid arthritisExpert Opin Biol Ther20121291277128922849354
   PubMed Web of Science ®Google Scholar
• AltenRMaleitzkeTTocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseaseAnn Med201345435736323650978
   PubMed Web of Science ®Google Scholar
• SchiffMSubcutaneous abatacept for the treatment of rheumatoid arthritisRheumatology (Oxford)201352698699723463804
   PubMed Web of Science ®Google Scholar
• NishimotoNTeraoKMimaTNakaharaHTakagiNKakehiTMechanisms and pathologic significances in increase in serum interleukine-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood2008112103959396418784373
   PubMed Web of Science ®Google Scholar
• OhtaSTsuruTTeraoKMechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)J Clin Pharmacol201454110911924115082
   PubMed Web of Science ®Google Scholar
• roche-trials.com [homepage on the internet]F. Hoffman-La Roche LtdClinical trial result information: protocol number NA25220ClinicalTrials.gov identifier NCT 01232569 Available from http://www.roche-trials.com/studyResultGet.action?studyResultNumber=NA25220Accessed February 1, 2014
   Google Scholar
• KivitzAOlechEBorofskyMAThe safety and efficacy of tocilizumab subcutaneous in combination with traditional DMARDS in patients with moderate to severe rheumatoid arthritis up to 48 weeks (BREVACTA)Arthritis Rheum201365s604s605
   Google Scholar
• BurmesterGRRubbert-RothACantagrelAA randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)Ann Rheum Dis2014731697423904473
   PubMed Web of Science ®Google Scholar
• OgataATanimuraKSugimotoTPhase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritisArthritis Care Res (Hoboken)201466334435423983039
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamammotoKStudy of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapyMod Rheumatol2009191121918979150
   PubMed Web of Science ®Google Scholar
• Al-ShakarchiIGullickNJScottDLCurrent perspectives on tocilizumab for the treatment of rheumatoid arthritis: a reviewPatient Prefer Adherence2013765366623869169
   PubMed Web of Science ®Google Scholar
• SchoelsMMvan der HeijdeDBreedveldFCBlocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementAnn Rheum Dis201372458358923144446
   PubMed Web of Science ®Google Scholar
• DougadosMKisselKSheeranTAdding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)Ann Rheum Dis2013721435022562983
   PubMed Web of Science ®Google Scholar
• ByberkVPÖstörAJKAlvaro-GraciaJTocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practiceAnn Rheum Dis201271121950195422615456
   PubMed Web of Science ®Google Scholar
• WeinblattMEKremerJCushJTocilizumab monotherapy or in combination with non-biologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice studyArthritis Care Res (Hoboken)201365336237122972745
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamomotoKKawaiSTakeuchiTAzumaJLong-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension studyAnn Rheum Dis200968101580158419019888
   PubMed Web of Science ®Google Scholar
• NishimotoNAmanoKHirabayashiYDrug free remission/low disease activity after cessation of tocilizumab (Actemra) monotherapy (DREAM) studyMod Rheumatol2014241172524261754
   PubMed Web of Science ®Google Scholar
• LeffersHCØstergaardMGlintborgBEfficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registryAnn Rheum Dis20117071216122221551512
   PubMed Web of Science ®Google Scholar
• SmolenJSMartinez AvilaJCAletahaDTocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destructionAnn Rheum Dis201271568769322121130
   PubMed Web of Science ®Google Scholar
• SchiffMHKremerJMJahresAIntegrated safety in tocilizumab clinical trialsArthritis Res Ther2011135R14121884601
   PubMed Web of Science ®Google Scholar
• CampbellLChenCBhagatSSParkerRAOstorAJRisk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trialsRheumatology (Oxford)201150355256221078627
   PubMed Web of Science ®Google Scholar
• Gómez-ReinoJBiologics monotherapy as initial treatment in patients with early rheumatoid arthritisRheumatology (Oxford)201251Suppl 53137
   Web of Science ®Google Scholar
• GabayCEmeryPvan VollenhovenRTocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised double-blind, controlled phase 4 trialLancet201338198771541155023515142
   PubMed Web of Science ®Google Scholar
• DasSVitalEMHortonSAbatacept or tocilizumab after rituximab arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapyAnn Rheum Dis201473590991224385201
   PubMed Web of Science ®Google Scholar
• ChoquetteDArundineMThomasOLarge discrepancy between expected and observed ratios of biologic treated rheumatoid arthritis patients also compliant on DMARDSAnn Rheum Dis201170197
   Google Scholar
• EmeryPSebbaAHuizingaTWBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisAnn Rheum Dis201372121897190423918035
   PubMed Web of Science ®Google Scholar
• SinghJAWellsGAChristensenRAdverse effects of biologics: a network meta-analysis and Cochrane overview (review)Cochrane Database Syst Rev2011162CD00879421328309
   PubMed Web of Science ®Google Scholar
• SchellekensHThe immunogenicity of therapeutic proteinsDiscov Med201094956056420587346
   PubMed Web of Science ®Google Scholar
• FavalliEGBiggioggeroMMarchesoniAMeroniPLSurvival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategiesRheumatology (Oxford) Epub2014412
   Web of Science ®Google Scholar
• GolmiaRPScheinbergMARetention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospitalEinstein (Sao Paulo)201311449249424488390
   PubMedGoogle Scholar
• NishimotoNAmanoKHirabayashiYRetreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) studyMod Rheumatol2014241263224261755
   PubMed Web of Science ®Google Scholar